-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Upgrades NeoGenomics to Outperform, Raises Price Target to $25

Benzinga·04/29/2026 13:10:09
Listen to the news
Leerink Partners analyst Puneet Souda upgrades NeoGenomics (NASDAQ:NEO) from Market Perform to Outperform and raises the price target from $12 to $25.